Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00444912 | The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD) | completed | Phase 2 | 30 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 13, 2014 | clinicaltrials |
| NCT02081937 | CART-19 Immunotherapy in Mantle Cell Lymphoma | unknown | Phase 1 / Phase 2 | 2 | Chinese PLA General HospitalOTHER | 1 | Mar 11, 2014 | clinicaltrials |
| NCT00396266 | AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF | completed | Phase 2 | 22 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00970021 | Agaricus Blazei Murill in Patients With Multiple Myeloma | completed | Phase 2 | 39 | Ullevaal University HospitalOTHER | 1 | Feb 25, 2014 | clinicaltrials |
| NCT00665314 | Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM). | completed | Phase 2 | 5 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Feb 11, 2014 | clinicaltrials |
| NCT00499239 | A Trial of GS-9219 in Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin's Lymphoma (NHL) or Multiple Myeloma (MM) | terminated | Phase 1 / Phase 2 | 32 | Gilead SciencesINDUSTRY | 3 | Feb 4, 2014 | clinicaltrials |
| NCT00394836 | HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab | completed | Phase 2 | 116 | GlaxoSmithKlineINDUSTRY | 1 | Jan 29, 2014 | clinicaltrials |
| NCT00750815 | Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 58 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 20, 2014 | clinicaltrials |
| NCT00617591 | Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) | completed | Phase 2 | 57 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Jan 17, 2014 | clinicaltrials |
| NCT00439231 | Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | completed | Phase 2 | 33 | Georg Aue, M.D.NIH | 1 | Jan 13, 2014 | clinicaltrials |
| NCT02027220 | Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma | unknown | Phase 2 | 60 | Second Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 6, 2014 | clinicaltrials |
| NCT00308087 | Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma(PREMIER) | terminated | Phase 2 | 75 | Genzyme, a Sanofi CompanyINDUSTRY | 2 | Dec 27, 2013 | clinicaltrials |
| NCT00656812 | Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma | completed | Phase 2 | 40 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Dec 24, 2013 | clinicaltrials |
| NCT01933282 | MESA Treatment for NK/T Cell Lymphoma(MTN) | unknown | Phase 2 | 100 | Air Force Military Medical University, ChinaOTHER | 1 | Dec 24, 2013 | clinicaltrials |
| NCT00412919 | Study of Azacitidine to Treat Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 7 | Bayside HealthOTHER_GOV | 1 | Dec 16, 2013 | clinicaltrials |
| NCT01090973 | Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL) | terminated | Phase 2 | 1 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 16, 2013 | clinicaltrials |
| NCT00899353 | Prevention of Disease Progression in Early Stage Indolent B Cell Malignancies. (SMM) | terminated | Phase 2 | 16 | Marshall UniversityOTHER | 1 | Dec 12, 2013 | clinicaltrials |
| NCT01854372 | Rituximab-HyperCVAD (R-HCVAD) Alternating With Rituximab-Methotrexate-Cytarabine- (R-MC) in Newly Diagnosed Patients With Diffuse Large B-Cell Lymphoma With MYC-Rearrangement. | withdrawn | Phase 2 | 0 | The University of Texas Health Science Center at San AntonioOTHER | 0 | Dec 10, 2013 | clinicaltrials |
| NCT00185445 | Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHL | completed | Phase 2 | 62 | Genzyme, a Sanofi CompanyINDUSTRY | 1 | Dec 4, 2013 | clinicaltrials |
| NCT00373906 | Velcade in MALT Lymphoma Patients | completed | Phase 2 | 16 | Medical University of ViennaOTHER | 0 | Nov 27, 2013 | clinicaltrials |
| NCT00205751 | Thalidomide/Dexamethasone vs MP for Induction Therapy and Thalidomide/Intron A vs Intron A for Maintenance Therapy | completed | Phase 2 / Phase 3 | 350 | Austrian Forum Against CancerOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00361088 | A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 42 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT00814983 | Myeloablative Allogeneic Stem Cell Transplantation Using a Naive T-Cell Depleted Peripheral Blood Stem Cell Graft | terminated | Phase 1 / Phase 2 | 15 | Duke UniversityOTHER | 0 | Nov 25, 2013 | clinicaltrials |
| NCT00883623 | A Trial of Treatment With Lenalidomide-Melphalan-Dexamethasone in Patients With Primary (AL) Amyloidosis(LEOMEX) | completed | Phase 2 | 50 | Heidelberg UniversityOTHER | 1 | Nov 25, 2013 | clinicaltrials |
| NCT01010295 | A Clinico-Pathological Study to Investigate the Possible Infective Causes of Non-Hodgkin Lymphoma of the Ocular Adnexae(IELSG27) | completed | Phase 2 | 54 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 4 | Nov 25, 2013 | clinicaltrials |
| NCT01164267 | Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL) | completed | Phase 2 | 30 | International Extranodal Lymphoma Study Group (IELSG)OTHER | 3 | Nov 25, 2013 | clinicaltrials |
| NCT01168804 | Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma(BBD) | completed | Phase 2 | 79 | Austrian Forum Against CancerOTHER | 2 | Nov 25, 2013 | clinicaltrials |
| NCT01500161 | Pooled Unrelated Donor Umbilical Cord Blood Transplant For Hematologic Malignancy Needing Allogeneic Stem Cell Transplant Without Related HLA-Match | terminated | Phase 2 | 1 | Texas Oncology Cancer CenterINDUSTRY | 1 | Nov 25, 2013 | clinicaltrials |
| NCT01990144 | Rituximab Plus Bendamustine as Front Line Treatment in Frail Elderly (>70 Years) Patients With DLBCL: a Phase II Multicenter Study of the FIL | unknown | Phase 2 | 49 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Nov 21, 2013 | clinicaltrials |
| NCT01983761 | Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation | unknown | Phase 1 / Phase 2 | 25 | Targazyme, Inc.INDUSTRY | 1 | Nov 18, 2013 | clinicaltrials |
| NCT00483262 | Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 63 | Dana-Farber Cancer InstituteOTHER | 1 | Nov 11, 2013 | clinicaltrials |
| NCT00195871 | Safety and Efficacy of an Adult Acute Lymphoblastic Leukemia Chemotherapy for Adult Lymphoblastic Lymphoma | unknown | Phase 2 | 155 | Centre Henri BecquerelOTHER | 2 | Nov 7, 2013 | clinicaltrials |
| NCT01037517 | Trial of an Augmented Mobilization Strategy With Plerixafor (Mozobil®) in a Population at Risk for Poor Stem Cell Mobilization | completed | Phase 2 | 52 | CancerCare ManitobaOTHER | 1 | Oct 31, 2013 | clinicaltrials |
| NCT01361191 | Early Treatment Stratification Based on PET Scan Response to Chemotherapy in Patients With Diffuse Large B-cell Lymphoma(R-MEGACHOP) | completed | Phase 2 | 71 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Oct 30, 2013 | clinicaltrials |
| NCT00718640 | An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function | terminated | Phase 2 | 10 | Janssen-Ortho Inc., CanadaINDUSTRY | 1 | Oct 29, 2013 | clinicaltrials |
| NCT00044551 | Evaluation of Bay 59-8862 in Patients With Aggressive, Refractory Non-Hodgkin's Lymphoma | completed | Phase 2 | 29 | BayerINDUSTRY | 6 | Oct 14, 2013 | clinicaltrials |
| NCT00079456 | Temsirolimus in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Oct 11, 2013 | clinicaltrials |
| NCT00058461 | Combination Chemotherapy and Rituximab in Treating Young Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia | terminated | Phase 2 | 82 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00243035 | Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 64 | National Cancer Institute (NCI)NIH | 1 | Oct 8, 2013 | clinicaltrials |
| NCT00100477 | Use of Topotecan in Patients With Refractory Acute Leukemia | completed | Phase 2 | 10 | US Department of Veterans AffairsFED | 1 | Sep 25, 2013 | clinicaltrials |
| NCT00547365 | Human Immune Globulin in Treating Patients With Primary Amyloidosis That is Causing Heart Dysfunction | completed | Phase 1 / Phase 2 | 10 | University of TennesseeOTHER | 1 | Sep 19, 2013 | clinicaltrials |
| NCT00048555 | Safety and Efficacy of IDEC-114 in Combination With Rituxan in the Treatment of Non-Hodgkin's Lymphoma | completed | Phase 1 / Phase 2 | 90 | BiogenINDUSTRY | 1 | Sep 16, 2013 | clinicaltrials |
| NCT00575406 | Multicentre Study to Determine the Cardiotoxicity of R-CHOP Compared to R-COMP in Patients With Diffuse Large B-Cell Lymphoma(NHL-14) | completed | Phase 2 | 94 | Arbeitsgemeinschaft medikamentoese TumortherapieOTHER | 1 | Aug 30, 2013 | clinicaltrials |
| NCT00115193 | Pegfilgrastim Administered on the Same Day as Chemotherapy in Non-Hodgkin's Lymphoma | completed | Phase 2 | 77 | AmgenINDUSTRY | 0 | Aug 29, 2013 | clinicaltrials |
| NCT00026182 | Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin's Lymphoma | completed | Phase 2 | 99 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2013 | clinicaltrials |
| NCT01921790 | Avastin+ GemAOD As First-Line Treatment in NK/T Cell Lymphoma | unknown | Phase 2 | 30 | Sun Yat-sen UniversityOTHER | 1 | Aug 22, 2013 | clinicaltrials |
| NCT01923935 | Busulfan and Melphalan Conditioning in Multiple Myeloma | unknown | Phase 2 | 105 | Chonnam National University HospitalOTHER | 1 | Aug 19, 2013 | clinicaltrials |
| NCT00241371 | A Phase II Study of Clofarabine in Patients With Relapsed or Refractory Multiple Myeloma | terminated | Phase 2 | 8 | Washington University School of MedicineOTHER | 1 | Aug 13, 2013 | clinicaltrials |
| NCT01232712 | A Study to Assess the Safety and Efficacy of MUC1 Peptide Vaccine and hGM-CSF in Patients With MUC1-positive Tumor Malignancies | completed | Phase 1 / Phase 2 | 15 | Vaxil Therapeutics Ltd.INDUSTRY | 1 | Aug 9, 2013 | clinicaltrials |
Data updated 23 days agoSource updated Mar 13, 2014source: clinicaltrials